Midas has signed an agreement with Aegirbio, a diagnostic and biotech company in Sweden for the distribution of the Company's saliva test for COVID-19. Midas Pharma will initially sell the product in Germany and will include other markets where Midas is established. The agreement with Aegirbio allows Midas to participate in the fast-growing market for COVID-19 testing. With this cooperation Aegirbio will gain direct access to Europe's largest diagnostic market with well-established tests for COVID-19. Midas Pharma is also active in countries outside Germany through its international network, which enables Aegirbio to distribute the tests more quickly.
“For many years, Midas Pharma has been successfully supporting its customers in their projects. In this respect, we can draw on a well-established network of partners in the pharmaceutical industry both inside and outside Germany. This global partner network and our many years of expertise allow us a high degree of flexibility and are the ideal basis for our cooperation with Aegirbio and the related requirements. Rapid testing for COVID-19 is a growing market and a test with such a simple sampling method as saliva will have a huge advantage in the professional test sites and even more so when we can bring the product to the home use market."
"We have been in discussions with Midas Pharma for some time, whose network in the pharmaceutical world will fit our strategy perfectly. Partly through the initial penetration of the professional market, but also that together we aim to provide the market Germany with tests for home use."
Aegirbio is a joint venture combining core technologies from LifeAssays and Abreos Biosciences. LifeAssays is a diagnostics company based in Lund, Sweden, and owns the Magnia Point of Care and Point of Need reader technology.
Abreos Biosciences is a San Diego, California, based biotech and has developed the Veritope chemistry platform for detecting levels of biologic drugs in patient samples. Following several years of successful collaboration, Lifeassays and Abreos Biosciences will combine their highly complementary technologies in Aegirbio to create a leader in therapeutic drug monitoring of biologic drugs.
Midas Pharma is a mid-sized pharmaceutical company, based in Ingelheim, Germany, that offers products, services and expertise along the entire pharmaceutical value chain - from starting materials to market ready finished products.
With almost 250 employees in 11 locations worldwide, the Midas Group is represented in all important pharmaceutical markets and has excellent local competencies, local contacts and well-established networks.
As a catalyst for collaboration, Midas creates value by offering a wealth of expertise in project management while coordinating and connecting people, knowledge and resources to facilitate global pharmaceutical projects.
In addition to the sourcing, supply and development of Intermediates, Active Ingredients and Finished Products, Midas provides services in Business Development and Licensing, Contract Development, Contract Manufacturing, Quality Management, Regulatory / Medical Affairs, Supplier Relationship Management, Supply Chain Management, Biotechnology, Reference Products Sourcing, Warehousing, Pharmacovigilance, IP Management and Mergers & Acquisitions.
For laboratory and production work, Midas cooperates with carefully selected specialist partners. This approach is the key to our flexibility in creating solutions for a wide range of requirements.